Efficacy and Safety of Pimecrolimus Cream 1% in Patients (2 to 11 Years Old) With Mild to Moderate Facial Atopic Dermatitis

Completed · Phase 4 · Has a placebo group

Conditions studied: Atopic Dermatitis

In brief

This study is not being conducted in the United States of America (USA). Atopic dermatitis, also called eczema, is characterized by redness, papulation (skin elevation) and pruritus (skin itching). The active ingredient of pimecrolimus inhibits T-cell activation. These cells are involved in the inflammatory component of the disease. This study will test the safety and efficacy of pimecrolimus cream 1% in atopic dermatitis of the face in patients intolerant of, or dependent on, topical corticosteroids.

Key facts

Study ID

NCT00130364

Run by

Novartis

People needed

200

Starts

2005-08-01

Expected to finish

2006-08-01

Last updated by the study team

2008-01-15

Who can join

Age: 2 and older, up to 11. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Mild to moderate facial atopic dermatitis
• Patients intolerant of, or dependent on, topical corticosteroids

You may not qualify if…

• Concurrent skin diseases (infections)
• Immunocompromised
• Recently received phototherapy or systemic therapy

Where it is running

• This study is not being conducted in the United States — Novartis Pharmaceuticals, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.